Hagop M. Kantarjian

Hagop M. Kantarjian is one of the most prolific and highly cited cancer researchers globally, with over 2,400 publications and 320,383 citations (h-index 204). As Chairman of the Department of Leukemia at MD Anderson, he has transformed ALL treatment through clinical trials of novel therapies. His first authorship on the landmark TOWER trial (NEJM 2017) established blinatumomab's superiority over chemotherapy, directly leading to expanded FDA indications. Kantarjian received the 2023 ASCO David A. Karnofsky Memorial Award for outstanding clinical research contributions. His Hyper-CVAD regimen remains standard for ALL treatment.

Hagop M. Kantarjian博士是全球最多产、被引用次数最多的癌症研究者之一，拥有2,400多篇出版物和320,383次引用（h指数204）。作为MD安德森白血病科主任，他通过新疗法临床试验改变了ALL治疗。他作为里程碑式TOWER试验（NEJM 2017）的第一作者，确立了blinatumomab优于化疗，直接促成FDA扩展适应症。Kantarjian获得2023年ASCO Karnofsky纪念奖。他的Hyper-CVAD方案仍是ALL治疗标准。